Sandoz Chief Looks To Build On Recent Deals
CEO Richard Saynor Offers The Latest On Anti-Infectives, Generics And Biosimilars
With a number of recent deals under the firm’s belt in both generics and biosimilars, Sandoz CEO Richard Saynor talks to Generics Bulletin about how the firm is integrating new assets and building towards some key launches this year.
You may also be interested in...
Sandoz Unveils $400m+ Investment In Slovenian Biosimilars Plant
Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.
Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.
Sandoz’s Saynor Reflects On Industry Challenges
In the third and final part of his exclusive interview with Generics Bulletin, Sandoz CEO Richard Saynor discusses global off-patent industry challenges including antibiotics shortages, PBM behavior in the US and the UK’s VPAS rebate mechanism.